All studies
RecruitingTherapeutic exploratory (Phase II)Interventional

The Sahlgrenska Anti-VEGF (SAHLVE) Study - a Prospective Randomized Double-blind Comparison of Bevacizumab and Aflibercept in Patients With Neovascular Age-related Macular Degeneration

Wet age-related macular degeneration (wet AMD) is an eye condition where abnormal blood vessels leak fluid into the back of the eye, causing blurred central vision. Doctors usually treat this with regular injections into the eye to dry up the fluid and protect sight. This trial compares two common medicines, Avastin (bevacizumab) and Eylea (aflibercept). Both drugs aim to stop the leaking vessels, but researchers want to find out which medicine works for longer between treatments. Over two years, doctors will count how many injections patients need and check their eyesight, eye pressure, and retina thickness. They will also look at overall value for money and how each treatment affects daily living. The goal is to discover which option offers the best results with fewer hospital visits for patients.

At a glance

Status
Recruiting
Phase
Therapeutic exploratory (Phase II)
Sponsor
Vaestra Goetalandsregionen
Enrolment target
402
Start
30 Aug 2023

What is this study about?

Age-related macular degeneration, or AMD, is a common condition that affects the middle part of your vision. In the 'wet' type of AMD, tiny abnormal blood vessels grow in the retina at the back of the eye. These vessels can leak fluid and blood, which can quickly lead to blurred or distorted vision. To stop this damage, eye specialists use medicines that block a protein called VEGF, which helps stop the leakage.

Two widely used medicines are Avastin and Eylea. Both treatments have been shown to help protect sight, but they may differ in how long each injection lasts. In this study, doctors are directly comparing the two drugs in a 'double-blind' trial, which means neither you nor your doctor will know which of the two medicines you receive during the study.

The main goal of the research is to see how many injections people need over two years to keep their condition stable. Researchers will also measure how clear your vision remains, check how swollen the retina is, and monitor eye pressure. By comparing both drugs, doctors hope to learn how to keep wet AMD under control with fewer clinic visits and injections, which could save time for patients and help healthcare services like the NHS use resources more effectively.

Key takeaways

  • Compares two proven wet AMD eye medicines: Avastin and Eylea.
  • Aims to see which drug needs fewer injections over two years.
  • Open to adults aged 18 and over with wet age-related macular degeneration.
  • Involves regular eye check-ups, scans, and vision tests over a two-year period.
  • Participation is voluntary, and you can withdraw at any time without losing standard care.

Who may be eligible?

This trial is open to adults aged 18 and older who have been diagnosed with neovascular (wet) age-related macular degeneration. Both men and women are welcome to take part.

Because the study focuses specifically on wet AMD, you must have active leakage in your retina that requires treatment with eye injections. Your eye specialist will examine your eyes using special cameras and scans to confirm that you have this specific condition.

People with other serious eye problems that might interfere with the results or make eye injections unsafe may not be able to join. The hospital study team will check your full medical history and perform detailed eye tests before confirming if the trial is right for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am 18 years of age or older.
  2. I have been diagnosed with neovascular (wet) age-related macular degeneration.
  3. I am able to attend regular hospital eye clinic visits over a two-year period.
  4. I am willing to receive regular eye injections and undergo routine eye scans.
  5. I do not have other severe eye conditions that rule out injection treatments.
Answer every question to see your result.

What does participation involve?

If you join the trial, your participation will last for two years. During this time, you will visit the eye clinic regularly for check-ups and treatment. At each visit, doctors will test your sight on eye charts, measure the pressure inside your eye, and take detailed scans of your retina to see if there is any fluid buildup.

Depending on what your scans show, you will receive an injection of either Avastin or Eylea directly into your eye. Before any injection, the clinic team will thoroughly numb your eye with anaesthetic drops to keep you comfortable. You will also be asked to complete short questionnaires about how your vision affects your day-to-day activities and general well-being so doctors can measure your quality of life.

Potential risks and benefits

Taking part may help stabilise or even improve your eyesight, and you will receive regular, detailed monitoring from eye specialists throughout the two years. However, all eye injections carry some minor risks, such as temporary grittiness, redness, or a temporary rise in eye pressure. More serious complications, such as an eye infection or retinal damage, are very rare. You are completely free to leave the trial at any time, and doing so will never affect your standard NHS care or your relationship with your medical team.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Sweden

Common questions

Will the eye injections be painful?

The medical team uses numbing drops on your eye before the procedure. Most people feel a slight pressure or a mild pinch, but it should not be painful.

Can I choose which medicine I receive?

No. A computer randomly decides which medicine you get, and neither you nor your doctor will know which one it is. This ensures the results are completely fair.

How long does the study last?

The study runs for two years, during which you will have regular clinic visits for eye checks and treatment as needed.

Will I have to pay to take part in this trial?

No, you do not have to pay for the study treatments, clinic visits, or tests involved in the trial.

What happens if I decide I want to stop taking part?

You can leave the study at any time without giving a reason. Your doctors will continue to look after your eyes using standard treatment.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "The Sahlgrenska Anti-VEGF (SAHLVE) Study - a Prospective Ran…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.